Ogivri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer in cases where tumors overexpress the HER2 protein. Ogivri is also known by its drug name, trastuzumab-dkst. Ogivri is a biosimilar of herceptin. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
In about 25 percent of breast cancers, there is a genetic variation that causes tumor cells to produce extra receptors for a growth factor. This gene, known as human epidermal growth factor receptor 2 (HER2), causes the cancer to grow more aggressively. Ogivri is a member of a class of drugs called biologics. Ogivri is a monoclonal antibody designed to turn off the HER2 gene. Ogivri is believed to work by reducing the amount of growth factor receptors on cancer cells, thereby slowing the growth of tumors.
How do I take it?
Ogivri is given as an intravenous infusion once a week or once every three weeks.
Ogivri is available as a powder packaged in a vial.
The FDA-approved label for Ogivri lists common side effects including fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash.
Rare but serious side effects listed for Ogivri can include heart failure, lung damage, and severe infusion reactions.
For more details about this treatment, visit:
Ogivri — Viatris
Ogivri — RxList